A friend sent me this link to Stanford Research Institute's work in the development of an anti-angiogenic molecule, SR16388. Studies show that this molecule prevents angiogenesis (or new blood vessel development) and the growth of multiple myeloma cells. The new molecule is currently under development and is getting ready for early patient clinical trials. Click Here to read the SRI International article.
about the author
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd).
More on New in Myeloma
Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:
.svg_7bb6fd32-1b73-4ca9-9a2f-8fd6fc59d528.png?alt=media){kind=logo}
Follow Us
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2023 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811